At Lykos Therapeutics, our mission is to transform the way mental health is treated. We aspire to challenge the status quo through the development of novel therapies and therapeutic approaches to treat mental health conditions. With 30+ years of experience researching psychedelic-assisted therapies, we remain focused on following rigorous science from which we can develop and commercialize novel treatment options. 

Founded in 2014 by the non-profit Multidisciplinary Association for Psychedelic Studies (“MAPS”), we are a for-profit public benefit corporation (“PBC”). As a PBC, we consider the impact of our decisions on society just as we think about financial implications. Everything we do is looked at through a public benefit lens. To learn more, visit us at www.lykospbc.com. 

Lykos Therapeutics (formerly MAPS PBC)

We are proud to announce the FDA acceptance and priority review of our new drug application (NDA) filing for our investigational therapy for post-traumatic stress disorder #PTSD in adults. 

Learn more about this exciting milestone below.  

Lykos Therapeutics (formerly MAPS Public Benefit Corporation) announced that PLOS has published the first study comparing the effects of investigational MDMA-assisted therapy and therapy with placebo on emotional coping skills and self-experience in adults with severe PTSD. The study explored how changes in self-experience impacted PTSD scores in the Company’s Phase 3, randomized, double-blind placebo-controlled study (MAPP1), previously published in Nature Portfolio. 

Results showed that compared to therapy with placebo, MDMA-assisted therapy had a statistically significant greater improvement in all self-experience measures such as self-compassion and being in touch with oneself. 

MAPS PBC raised more than $100 million including conversion of previously issued convertible notes with the closing of our oversubscribed Series A financing. Learn more about this significant milestone:


Same commitment, new name! MAPS PBC is now Lykos Therapeutics. Selecting the name Lykos – wolf in Greek – was a purposeful decision made to represent bravery, courage, loyalty and intelligence, all things we embody at our company. 

MAPS PBC announced today that the American Medical Association CPT III codes for psychedelic-assisted therapy\ies, first announced in July 2023, are now in effect. These temporary codes are assigned to emerging technologies to facilitate reimbursement and support access to psychedelic therapies in the United States, if such therapies receive regulatory approval by the #FDA. 
 
The new CPT codes will provide healthcare providers with a means to seek coverage and reimbursement for delivering psychedelic-assisted therapy if approved by the FDA.


Woven Science is a company specializing in mental health solutions and treatment.

Woven Science

GH Research is a provider of therapeutics for the management of mental diseases.

GH Research

Small Pharma is a company focused on developing novel mental health treatments.

Small Pharma

Lykos Therapeutics is a healthcare company focused on revolutionizing mental health treatment.

Lykos Therapeutics

doc.ai is a company offering advanced AI-driven healthcare solutions, including mental health.

doc.ai

Lightship is a company providing innovative mental health technology and resources.

Lightship

Alphaeon is a company specializing in mental health and wellness solutions.

Alphaeon

Lykos PBC is a mental health technology company that specializes in creating solutions to improve access to mental health care. The company focuses on leveraging technology to connect individuals with mental health professionals and resources, aiming to make mental health care more accessible and effective.

Lykos PBC

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 12, 2024 6:47 PM	1c8dba25
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 4, 2024 10:53 AM	ba1f5366
crunchbase profile	general
li profile	general	May 12, 2024 6:47 PM	5548448b
translate crunchbase fundingrounds	general
peers	general
news basic	general	May 12, 2024 6:47 PM	e40167c2
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:LYKOSPBC

Lykos PBC